Sökning: id:"swepub:oai:DiVA.org:umu-127523" >
Advanced phase chro...
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era : a report from the Swedish CML register
-
- Söderlund, Stina (författare)
- Uppsala universitet,Hematologi,Uppsala University, Sweden; University of Uppsala Hospital, Sweden
-
- Dahlén, Torsten (författare)
- Karolinska Institutet,Karolinska Institute,Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
-
- Sandin, Fredrik (författare)
- Reg Canc Ctr Uppsala-Örebro, Uppsala, Sweden,Regional Cancer Centre Uppsala Örebro, Sweden
-
visa fler...
-
- Olsson-Strömberg, Ulla (författare)
- Uppsala universitet,Hematologi,Uppsala University, Sweden; University of Uppsala Hospital, Sweden
-
- Creignou, Maria (författare)
- Linkoping Univ Hosp, Dept Haematol, Linkoping, Sweden,Linköping University Hospital,Region Östergötland, Hematologiska kliniken US
-
- Dreimane, Arta (författare)
- Linköpings universitet,Institutionen för klinisk och experimentell medicin,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US
-
- Lübking, Anna (författare)
- Skane Univ Hosp, Dept Haematol Oncol & Radiat Phys, Lund, Sweden,Skåne University Hospital, Sweden
-
- Markevärn, Berit (författare)
- Umea Univ Hosp, Dept Haematol, Umea, Sweden,Norrland University Hospital,Umeå University Hospital, Sweden
-
- Själander, Anders (författare)
- Umeå University,Umeå universitet,Medicin,Sundsvall Research Unit, Umeå University,Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden,Umeå University, Sweden
-
- Wadenvik, Hans (författare)
- Sahlgrens Univ Hosp, Sect Haematol & Coagulat, Gothenburg, Sweden,Sahlgrens University Hospital, Sweden
-
- Stenke, Leif (författare)
- Karolinska Institutet,Karolinska Institute,Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
-
- Richter, Johan (författare)
- Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden
-
- Höglund, Martin (författare)
- Uppsala universitet,Hematologi,Uppsala University, Sweden; University of Uppsala Hospital, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2016-08-19
- 2017
- Engelska.
-
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 98:1, s. 57-66
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVES: The primary goal in management of chronic phase (CP) chronic myeloid leukaemia (CML) is to prevent disease progression to accelerated phase (AP) or blast crisis (BC). We have evaluated progression rates in a decentralised healthcare setting and characterised patients progressing to AP/BC on TKI treatment.METHODS: Using data from the Swedish CML register, we identified CP-CML patients diagnosed 2007-2011 who progressed to AP/BC within 2 yrs from diagnosis (n = 18) as well as patients diagnosed in advanced phase during 2007-2012 (n = 36) from a total of 544 newly diagnosed CML cases. We evaluated baseline characteristics, progression rates, outcome and adherence to guidelines for monitoring and treatment.RESULTS: The cumulative progression rate at 2 yrs was 4.3%. All 18 progression cases had been treated with imatinib, and six progressed within 6 months. High-risk EUTOS score was associated to a higher risk of progression. Insufficient cytogenetic and/or molecular monitoring was found in 33%. Median survival after transformation during TKI treatment was 1.4 yrs. In those presenting with BC and AP, median survival was 1.6 yrs and not reached, respectively.CONCLUSION: In this population-based setting, progression rates appear comparable to that reported from clinical trials, with similar dismal patient outcome. Improved adherence to CML guidelines may minimise the risk of disease progression.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- chronic myeloid leukaemia
- accelerated phase
- blast crisis
- tyrosine kinase inhibitor
- population-based
- Accelerated phase
- Blast crisis
- Chronic myeloid leukaemia
- Population-based
- Tyrosine kinase inhibitor
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Söderlund, Stina
-
Dahlén, Torsten
-
Sandin, Fredrik
-
Olsson-Strömberg ...
-
Creignou, Maria
-
Dreimane, Arta
-
visa fler...
-
Lübking, Anna
-
Markevärn, Berit
-
Själander, Ander ...
-
Wadenvik, Hans
-
Stenke, Leif
-
Richter, Johan
-
Höglund, Martin
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Umeå universitet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet
-
Linköpings universitet